Resources

TB partners, guidelines, research, and tools all in one place.

Guidelines

Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

CDC Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection

US Guidelines: Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019

Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America

Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edition / 2022 Updates

Guidelines for TB and LTBI

ATS/CDC/ERS/IDSA Clinical Practice Guideline Update on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis

Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis

ATS/CDC/IDSA Guidelines for Treatment of Drug-Susceptible Tuberculosis

National Tuberculosis Coalition of America (NTCA) Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings

Diagnosis of Tuberculosis in Children and Adults, American Thoracic Society

Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases, 2007, American Thoracic Society

Guidelines for Environmental Infection Control in Health-Care Facilities, 2003, CDC

An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy

Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC







Tools 

TST/IGRA Interpreter - Estimates the risk of active tuberculosis for an individual with a tuberculin skin test reaction of ≥5mm, based on his/her clinical profile. It is intended for adults tested with standard tuberculin (5 TU PPDS, or 2 TU RT-23) and/or a commercial Interferon Gamma release assay (IGRA).this tool estimates the risk of active tuberculosis for an individual with a tuberculin skin test reaction of ≥5mm, based on his/her clinical profile. It is intended for adults tested with standard tuberculin (5 TU PPDS, or 2 TU RT-23) and/or a commercial Interferon Gamma release assay (IGRA).

TB Infectious Period Interactive Calendar - Assists with determining the infectious period during a TB contact investigation. It aids in identifying the period of time that an infected person may transmit TB disease to others, based on CDC’s 2005 guidelines. This tool should not be used as a substitute for professional judgment in determining infectious period. This tool should be used in partnership with a TB expert who can walk you through the dose counting process.
TB Treatment Dose Counting - This dose counting tool is used to accurately track the administration of daily TB medication doses throughout the treatment period using an online tool. This tool is for teaching purposes only and should not be used for patient treatment.  This tool should be used in partnership with a TB expert who can walk you through the dose counting process.
BPaL Monitoring - Word document
MDR Weekly Assessment - Word document
BPaL Regimen, P Woods NJ - Word document